

NB Health Laboratory Announces the Completion of Series C Third-Party Allotment of Capital Aimed to Accelerate Research and Development of New GPCR Antibody Pipeline

NB Health Laboratory Co., Ltd. (Headquarters: Kita-ku, Sapporo, Representative Director: Kiyoshi Takayama, hereinafter referred to as "NBHL") has completed a total of 7.46 million USD in Series C financing through a third-party allotment. NBHL is a biotechnology company discovering, developing and commercializing innovative medicines for severe diseases characterized by highly unmet medical needs. With this funding, NBHL will accelerate further preclinical and clinical development of the new anti-G protein coupled receptor ("GPCR") antibody ("anti-GPCR antibody") pipeline and expand the search for anti-GPCR antibody seeds utilizing its unique antibody drug discovery platform (MoGRAA® discovery engine).

The additional financing was invested by Healthcare Innovation Investment Limited Partnership, which is newly operated and managed by Healthcare Innovation Co., Ltd. (President: Mitsuru Miyata, hereinafter referred to as "HCI"), and the cumulative total of Series C financing has increased to 7.46 million USD.

"We are very grateful for the trust and investment from venture capital firms such as HCI who are very familiar with investing in the pharmaceutical industry and biotechnology companies. With this funding, we will be able to further develop multiple preclinically developed antibodies for the treatment of autoimmune diseases, fibrosis, cancer and severe viral infections, and expand the search for new GPCR antibody seeds continuously," said Kiyoshi Takayama, Founder and Director of NBHL.

Mr. Mitsuru Miyata, President and CEO of HCI, said, "I have been interested in NBHL having a unique antibody development technology for GPCR, which is the target of drug discovery for 20% of pharmaceutical products. A few years ago, NBHL has changed its business model and started the development of its own pipeline followed by licensing activities to both domestic and foreign pharmaceutical companies enthusiastically to the extent that it has achieved some alliances already. Besides, anti-GPCR antibody pipeline under development is also attractive. We will spare no effort to provide various support in order to make a big leap forward of NBHL as a venture company that will lead the bio industry in Japan. "

About Healthcare Innovation Co., Ltd.

Healthcare Innovation Co., Ltd was established in February 2017 by Mr. Yoshihiro Otaki and Mr. Mitsuru Miyata, opinion leaders of the Japanese bio industry, with the aim of discovering, investing in and nurturing "healthcare-related venture companies that will open up the future" who will be a leader in the rapidly developing healthcare industry. For more information about the company, please visit <https://hcinnovation.jp/>.

About NB Health Laboratory Co., Ltd.

NB Health Laboratory Co., Ltd. (NBHL) is a biotechnology company founded in 2006 that specializes in the creation, development and commercialization of innovative drugs for respiratory diseases, chronic inflammation, and respiratory infections such as COVID-19 and influenza. With expertise in the production of functional antibodies targeting GPCRs, NBHL is pioneering new areas of GPCR-targeted drug discovery that benefit people's health. For more information about the company, please visit <https://nbhl.co.jp/jp/>.

About G Protein-Coupled Receptor (GPCR)

GPCRs are a group of proteins existing on the cell membrane and about 400 types are available in the human body. It has a structure that sews the cell membrane seven times, and acts as a receptor that receives various external stimuli and transmits them into the cell. In recent years, GPCRs have been shown to be associated with various diseases one after another. Global sales of all new drugs targeting GPCRs reached 7,953.6 billion JPY (12.7% of the total) in 2020, and 113 items (19.0% of the total) were sold, making them extremely important as drug targets.